Efectos clínicos del tratamiento con hidroxiurea en pacientes de 3 a 17 años, con diagnóstico de anemia falciforme Hospital Infantil Dr. Robert Reid Cabral, período Septiembre 2009-2015 Santo Domingo, República Dominicana
Files
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
Date
Authors
Subject
hydroxyurea
sickle cell
hospitalizations
transfusions
hidroxiurea
falcemia
crisis
hospitalizaciones
transfusiones
sickle cell
hospitalizations
transfusions
hidroxiurea
falcemia
crisis
hospitalizaciones
transfusiones
Language:
Journal Title
Journal ISSN
Volume Title
Publisher
Intituto Tecnológico de Santo Domingo (INTEC)
Objetivo: Analizar los efectos clínicos de la hidroxiurea, demostrada como la única terapia modificadora de la anemia falciforme.
Método: El presente estudio es de carácter observacional y descriptivo. Población: 210 pacientes con anemia falciforme bajo terapia con hidroxiurea. Muestra: muestreo no probabilístico por conveniencia, constituida por los pacientes de la población que cumplían con los criterios de inclusión (92 pacientes).
Resultados: De los pacientes estudiados (100%); el 87% fueron falcémicos HbSS, que empezaron su terapia entre los 3 y 9 años (60%), con un número promedio de cinco seguimientos en 1-2 años de terapia. Se observó una reducción importante (51%) (p<0.00001) en el número total de crisis posterior al tratamiento con hidroxiurea, y reducción de ingresos hospitalarios (57%) (p=0.000019) y número de transfusiones sanguíneas (84%) (p=0.000033). Más tiempo con la terapia se traduce en: aumento Hb y VCM, disminución de leucocitos y plaquetas, y una variación dentro de los límites de los perfiles hepático y renal.
Discusión y conclusiones: La hidroxiurea es bien tolerada, segura y eficaz, demostrando reducción significativa en el número de crisis, transfusiones sanguíneas y hospitalizaciones, así como aumento de la hemoglobina y VCM. No se documentaron efectos secundarios importantes.
Objective: Analyze the clinical effects of hydroxyurea, as the only therapy proven to be a modifier of sickle cell disease. Method: This is a descriptive and observational study. Population: 210 patients with sickle cell anemia who were under therapy with hydroxyurea. Sample: non-probability sampling for convenience, 92 who met the inclusion criteria. Results: Of the patients studied (100%), most were Sickle Cell Disease HbSS (87%), who began their therapy between 3 and 9 years (60%), averaging five follow up consults in 1-2 years of therapy. A reduction (51%) (p<0.00001) in the total number of all subsequent crises to treatment with hydroxyurea was observed. Also, an important reduction in hospital admissions (57%) (p=0.000019) and blood transfusions (84%) (p=0.000033) was documented. Longer therapy results in: increased Hb and MCV, decreased leukocytes and platelets and a variation within the limits of the liver and kidney profiles. Discussion and conclusion: Hydroxyurea is well tolerated, safe and effective for most patients, showing significant reduction in the number of crises, blood transfusions and hospitalizations, and increased hemoglobin and mean corpuscular volume. No significant side effects were reported.
Objective: Analyze the clinical effects of hydroxyurea, as the only therapy proven to be a modifier of sickle cell disease. Method: This is a descriptive and observational study. Population: 210 patients with sickle cell anemia who were under therapy with hydroxyurea. Sample: non-probability sampling for convenience, 92 who met the inclusion criteria. Results: Of the patients studied (100%), most were Sickle Cell Disease HbSS (87%), who began their therapy between 3 and 9 years (60%), averaging five follow up consults in 1-2 years of therapy. A reduction (51%) (p<0.00001) in the total number of all subsequent crises to treatment with hydroxyurea was observed. Also, an important reduction in hospital admissions (57%) (p=0.000019) and blood transfusions (84%) (p=0.000033) was documented. Longer therapy results in: increased Hb and MCV, decreased leukocytes and platelets and a variation within the limits of the liver and kidney profiles. Discussion and conclusion: Hydroxyurea is well tolerated, safe and effective for most patients, showing significant reduction in the number of crises, blood transfusions and hospitalizations, and increased hemoglobin and mean corpuscular volume. No significant side effects were reported.
Description
Type
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/publishedVersion
Source
Science and Health; Vol 2 No 3 (2018): Science and Health, september-december; 27-34
Ciencia y Salud; Vol. 2 Núm. 3 (2018): Ciencia y Salud, septiembre-diciembre; 27-34
2613-8824
2613-8816
10.22206/cysa.2018.v2i3
Ciencia y Salud; Vol. 2 Núm. 3 (2018): Ciencia y Salud, septiembre-diciembre; 27-34
2613-8824
2613-8816
10.22206/cysa.2018.v2i3